Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedApr 05, 2026
DataAggregated Company Financials
Companies314
  • 7D3.8%
  • 3M3.0%
  • 1Y37.2%
  • YTDn/a

Over the last 7 days, the Pharma industry has risen 3.8%, driven by gains from Eli Lilly of 6.5%. During this same period, the Prestige Consumer Healthcare underperformed, falling 11%. This means that the industry has gained 37% over the past year. Earnings are forecast to grow by 11% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Apr 2026US$2.3tUS$405.9bUS$72.5b16.4x31.6x5.6x
Tue, 03 Mar 2026US$2.4tUS$405.9bUS$72.4b20x33.5x6x
Thu, 29 Jan 2026US$2.3tUS$405.1bUS$73.9b20.3x31x5.7x
Sat, 27 Dec 2025US$2.3tUS$402.8bUS$71.4b19.9x31.7x5.6x
Mon, 24 Nov 2025US$2.2tUS$402.7bUS$71.4b19.9x30.4x5.4x
Wed, 22 Oct 2025US$1.9tUS$389.2bUS$63.5b18.4x29.6x4.8x
Fri, 19 Sep 2025US$1.8tUS$387.9bUS$60.9b18.4x29.2x4.6x
Sun, 17 Aug 2025US$1.7tUS$387.8bUS$61.0b18.9x28.5x4.5x
Tue, 15 Jul 2025US$1.8tUS$382.7bUS$61.3b18.3x28.8x4.6x
Thu, 12 Jun 2025US$1.8tUS$382.7bUS$61.2b18.3x29x4.6x
Sat, 10 May 2025US$1.7tUS$382.6bUS$61.1b17x27.6x4.4x
Mon, 07 Apr 2025US$1.7tUS$379.9bUS$41.3b16x40.4x4.4x
Wed, 05 Mar 2025US$2.0tUS$381.1bUS$39.3b16.3x50.2x5.2x
Fri, 31 Jan 2025US$1.8tUS$370.4bUS$29.8b18.8x61.8x5x
Sun, 29 Dec 2024US$1.8tUS$369.4bUS$31.1b16.9x58x4.9x
Tue, 26 Nov 2024US$1.8tUS$373.8bUS$30.6b19.5x59.2x4.8x
Thu, 24 Oct 2024US$2.0tUS$365.3bUS$23.7b18.2x84.9x5.5x
Sat, 21 Sep 2024US$2.0tUS$364.2bUS$25.4b18.9x80.3x5.6x
Mon, 19 Aug 2024US$2.0tUS$362.1bUS$21.8b17.3x91.7x5.5x
Wed, 17 Jul 2024US$2.0tUS$355.6bUS$13.8b15.7x146.5x5.7x
Fri, 14 Jun 2024US$1.9tUS$358.3bUS$14.1b15.5x137.9x5.4x
Sun, 12 May 2024US$1.9tUS$358.2bUS$13.7b19.4x135.2x5.2x
Tue, 09 Apr 2024US$1.9tUS$355.2bUS$22.8b23.8x82.2x5.3x
Thu, 07 Mar 2024US$1.9tUS$355.3bUS$22.5b23.3x83.8x5.3x
Sat, 03 Feb 2024US$1.8tUS$353.1bUS$22.0b31.7x81.4x5.1x
Mon, 01 Jan 2024US$1.7tUS$375.2bUS$33.8b31.9x49.9x4.5x
Wed, 29 Nov 2023US$1.6tUS$375.1bUS$33.9b26.1x48.3x4.4x
Fri, 27 Oct 2023US$1.6tUS$383.5bUS$46.5b14.4x34.9x4.2x
Sun, 24 Sep 2023US$1.7tUS$381.8bUS$43.9b19.9x38.3x4.4x
Tue, 22 Aug 2023US$1.8tUS$381.6bUS$44.1b19.9x40.4x4.7x
Thu, 20 Jul 2023US$1.7tUS$392.8bUS$60.2b18.8x27.7x4.2x
Sat, 17 Jun 2023US$1.7tUS$392.8bUS$60.1b19x29x4.4x
Mon, 15 May 2023US$1.7tUS$392.9bUS$60.4b20.4x28.7x4.4x
Wed, 12 Apr 2023US$1.7tUS$401.3bUS$68.5b16.9x24.1x4.1x
Price to Earnings Ratio

24.1x


Total Market Cap: US$1.7tTotal Earnings: US$68.5bTotal Revenue: US$401.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.6x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 31.6x which is lower than its 3-year average PE of 53.6x.
  • The 3-year average PS ratio of 4.9x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Comparison

How does U.S. Pharma compare with similar industries?

US Market3.46%
Healthcare3.50%
Pharma3.83%
Pharma3.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$935.586.5%
+US$51.3b		26.7%PE40.6x
PFE PfizerUS$28.324.7%
+US$7.3b		23.3%PE20.8x
JNJ Johnson & JohnsonUS$243.041.1%
+US$6.2b		58.6%PE21.8x
MRK MerckUS$120.871.0%
+US$3.1b		48.4%PE16.4x
RGC Regencell Bioscience HoldingsUS$30.8020.0%
+US$2.5b		3,533.7%PB3133.6x

Latest News

JNJ
US$243.04
Johnson & Johnson
7D
1.1%
1Y
58.6%

Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030

Apr 04
PBH
US$52.48
Prestige Consumer Healthcare
7D
-11.4%
1Y
-36.7%

PBH: Buybacks And Brand Investment Will Support Future Capital Deployment Opportunities

Analysts have adjusted the price target for Prestige Consumer Healthcare to $78.50 from $77.83, reflecting updated views on revenue growth assumptions, profit margins, and the future P/E multiple. What's in the News Completed repurchase of 3,064,806 shares, representing 6.24% of shares, for a total of $207m under the buyback program announced on May 14, 2024, including 766,559 shares, or 1.59%, bought between October 1, 2025 and December 31, 2025 for $45.82m (Key Developments).
ZTS
US$117.94
Zoetis
7D
4.0%
1Y
-22.3%

ZTS: Share Repurchases And Execution Recovery Will Support Medium-Term Upside

Analyst targets on Zoetis have shifted modestly, with a small net reduction in the Street price target in dollar terms as some analysts cite concerns about organic growth and an innovation "air pocket," even as others make minor upward adjustments. Analyst Commentary Recent Street research on Zoetis reflects a split view, with some analysts emphasizing concerns around organic growth and an innovation air pocket, while others are adjusting targets in a more constructive way.
MRK
US$120.87
Merck
7D
1.0%
1Y
48.4%

MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside

Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.
LPCN
US$2.05
Lipocine
7D
-71.3%
1Y
-31.9%
TEVA
US$30.08
Teva Pharmaceutical Industries
7D
4.7%
1Y
118.0%

TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal

Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.
LLY
US$935.58
Eli Lilly
7D
6.5%
1Y
26.7%
NMRA
US$2.00
Neumora Therapeutics
7D
-14.2%
1Y
171.6%

CNS And Obesity Pipeline Will Create Long Term Value As Late Stage Data Emerges

Catalysts About Neumora Therapeutics Neumora Therapeutics focuses on developing brain penetrant medicines for neuropsychiatric, neurodegenerative, and metabolic diseases. What are the underlying business or industry changes driving this perspective?
ESPR
US$2.61
Esperion Therapeutics
7D
-4.7%
1Y
112.2%
RGC
US$30.80
Regencell Bioscience Holdings
7D
20.0%
1Y
3,533.7%
BMY
US$59.60
Bristol-Myers Squibb
7D
1.8%
1Y
7.8%
ALMS
US$23.37
Alumis
7D
-5.8%
1Y
132.5%
MAZE
US$28.71
Maze Therapeutics
7D
-5.5%
1Y
216.5%
PFE
US$28.32
Pfizer
7D
4.7%
1Y
23.3%
PLYX
US$7.14
Polaryx Therapeutics
7D
-8.3%
1Y
n/a
MANE
US$64.19
Veradermics
7D
-2.0%
1Y
n/a